Today ABH has more than 200 employees committed to producing and distributing Dermagraft, a breakthrough product for the treatment of diabetic foot ulcers. In addition to current efforts related to Dermagraft, the company continues to evaluate out-license and in-license opportunities to expand its role as one of the premier regenerative medicine companies in the world.

Asterand plc is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. Our mission is to provide human tissues and services to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with an increased likelihood of clinical success. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, we are uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From our offices in Royston (United Kingdom) and Detroit, Michigan we have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.

Avita Medical Limited is a publicly listed, global medical technology company trading on the Australian Stock Exchange (ASX:AVH). The company develops and distributes highly innovative products in Regenerative and Respiratory Medicine. The company's regenerative and tissue-engineered products provide revolutionary solutions utilising the patient's own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects.